In previous studies FGFR1 gene alterations have been observed in ~ 7-27% of all breast cancers (48), have been associated with poor prognosis, and constitute a critical mechanism underlying the development of treatment resistance to endocrine suppression via AIs and SERMs (48–50). This evidence concerns the gene FGFR1 and breast carcinoma.